



For Immediate Release

Nanōmix Inc. awarded NASA development subcontract

Project to demonstrate point of care diagnostics in support of flight research on the International Space Station

Emeryville, CA (October 30, 2012) – Nanōmix Inc., (Nanōmix), a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that the company had been awarded a development subcontract from Wyle under the National Aeronautics and Space Administration (NASA) Bioastronautics Contract. The subcontract was awarded to demonstrate the feasibility of using the company’s carbon nanotube based mobile diagnostics platform for future flight research in support of the International Space Station (ISS).

With the retirement of the Space Shuttle, biological sample return from the International Space Station will be challenging due to volume limitations on Soyuz. Rather than relying on sample return and ground-based analysis, in-flight analysis will provide “point of care” assessment of analytes of interest to the NASA biomedical research community. The goal of this effort is to demonstrate the potential for in-flight lab analysis through the development and validation of a panel of four (4) analytes for quantitative measurement in a multiplexed format.

"Nanōmix is excited to be working with Wyle to support NASA, further demonstrating the versatility of Omega-3, Nanōmix’s point-of-care (POC) platform, to provide lab quality results outside of traditional hospital settings and you don’t get much further out than the ISS.” said Garrett Gruener, CEO of Nanōmix. “The project builds upon the mobile diagnostics platform that Nanōmix is developing for use in first responder and emergency department settings.”

About Nanōmix Inc.

Nanōmix’s leadership in carbon nanotubes and nanoscale electronic sensors has enabled the development of the next generation of Point of Care testing systems where superior performance and rapid results can both be achieved in virtually any setting. Omega-3, the Nanōmix mobile diagnostic platform, performs multiple in-vitro diagnostic assays simultaneously from a single whole-blood sample. The compact size of the electronic and credit card sized disposable test cartridge can be configured to run a wide variety of tests from range of sample sources, including finger sticks.

For more information, visit: <http://www.nano.com>